Newport Beach, CA, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bitech Technologies Corporation , (“the Company” or “Bitech”) a global technology...
Presentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PTNEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics,...
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to...
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s...
RAPIDe-3, a global Phase 3 clinical study of deucrictibant for the on-demand treatment of HAE, to initiate within 1H24Results of...
ORION CORPORATION PRESS RELEASE05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684...
A New Era for HoneyStick in Canada, TPB Canada’s Stewardship Includes Icons Such as Zig-Zag, Clipper, Choice Leaf, HMP, Rebound...
The Company will provide an update on its leading asset BNC210 and their partnership strategyADELAIDE, Australia and CAMBRIDGE, Mass., Jan....
WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new...
Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today...
VALNEVA Declaration of shares and voting rights December 31, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain...
CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics...
Clinical portfolio substantially strengthened through business development in 2023; two phase 3 studies expected to start in 2024Cresemba in-market sales...
Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025MIAMI, Jan....
WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative...
LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose...
GRAD1405 uses Gradalis’ breakthrough gene silencing bi-shRNAi technology to specifically reduce the expression of certain mutated KRAS genesExisting therapies have...
TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to...